ROCKVILLE, Md., Feb. 23 STB Lifesaving TechnologiesŪ announced today $2.4 million was included in the FY2010 U.S. Department of Defense appropriations bill to advance the development of the Fibrin Adhesive STat (FASTŪ) dressing. This newly developed dressing is designed to be effective against all kinds of blood loss, including severe arterial and venous bleeding and could help save the lives of soldiers suffering from severe blood loss.
According to the Combat Casualty Care Research Program, eighty-six percent of combat-related deaths occur within 30 minutes of wounding, and fifty percent or more are attributable to uncontrolled hemorrhaging. With better products to control bleeding, such as the STB FASTŪ dressing, thousands of military and civilian lives could be saved.
"We are grateful for Senator Cardin's continued support for STBŪ and honored by the opportunity to serve the Department of Defense. If awarded to STBŪ, these funds, along with funds provided by our investors, will be used to accelerate the step up to cGMP manufacturing, and the necessary planning and pre-clinical work required to file for approval by the FDA to initiate human clinical trials," said Ron Peele, STBŪ's President.
Much of the clinical planning will involve advisors from the University of Maryland and MD Shock Trauma Center, who will also be involved in the in vivo efficacy testing, which will be conducted at a facility in Reisterstown, MD.
Founded in 2005, STB Lifesaving TechnologiesŪ (STBŪ) is a privately held, pre-clinical stage, biotechnology development company located in Rockville, Maryland. STBŪ which stands for "stop the bleeding", is focused on developing a comprehensive suite of products to stop serious and life threatening bleeding in trauma and surgical settings. With a strong proprietary position using its all-natural protein technology with five patents and one provisional patent pending, STBŪ's products will be indispensable to both the military and civilian medical markets.
SOURCE STB Lifesaving Technologies